Mazdutide: Burning Both Ends of the Energy Equation

Key Takeaway: Mazdutide, a weekly injection targeting both GLP-1 and glucagon receptors, achieved up to 18.1% body weight reduction in 32 weeks in a phase 2 study of U.S. adults with obesity. While these results place the drug in the same league as the most effective weight-loss treatments currently in development, the gastrointestinal side effects and notable treatment discontinuation rate observed at the highest dose warrant careful examination in future, larger trials.

A New Player Enters the Arena

For decades, the pharmacological treatment of obesity was overshadowed by failed drugs and modest outcomes. Even medications that managed to achieve a five or six percent weight loss were considered a victory. Then came the incretin revolution—semaglutide, tirzepatide—and suddenly, double-digit weight loss became a realistic clinical goal. Now, another powerful player is entering the scene. In a phase 2 study, a new weekly injection called mazdutide helped individuals with obesity lose an average of 18% of their body weight in just 32 weeks. What sets this drug apart is not just its efficacy but its mechanism of action: mazdutide doesn’t just suppress appetite. It may also accelerate the body’s own calorie-burning machinery.

Study Details

This was a 48-week, phase 2, randomized, placebo-controlled trial conducted with 179 adults across the United States with obesity or overweight with at least one weight-related comorbidity. The 179 participants were randomly assigned to receive either mazdutide (32 participants at 3-6 mg, 48 at 10 mg, and 51 at 16 mg) or placebo (48 participants). Participants received escalating doses of mazdutide or a matching placebo via weekly subcutaneous injection. The primary efficacy endpoint was the percentage change in body weight from baseline.

The results were striking. At week 32, the 10 mg dose achieved an average body weight reduction of 15.6%, while the 16 mg dose reached a reduction of 18.1%. In contrast, the loss in the placebo group was only 0.9%. The treatment differences versus placebo were highly statistically significant, with p-values below 0.0001 for all active doses^[1]. To put these numbers in context, in the landmark STEP 1 trial, semaglutide 2.4 mg demonstrated approximately 14.9% weight loss over 68 weeks^[2]. Although mazdutide appears to have achieved a similar or superior effect in about half the time, direct cross-trial comparisons should always be interpreted with caution.

The safety profile painted a familiar picture for this class of drugs. Gastrointestinal side effects—nausea, vomiting, diarrhea—were the most common adverse events. In the highest dose group (16 mg), 20% of participants discontinued treatment due to these effects. This rate will necessitate careful dose-titration strategies in future phase 3 trials.

The Dual-Action Mechanism: Why Two Receptors May Be Better Than One

To understand why mazdutide is generating excitement, it’s essential to grasp the biology it leverages. Most of the current blockbuster obesity medications work primarily through the GLP-1 receptor. GLP-1, or glucagon-like peptide-1, is a hormone released from the gut after a meal. It signals the brain to reduce appetite, slows stomach emptying to promote a longer feeling of fullness, and increases insulin secretion from the pancreas^[3]. Drugs like semaglutide mimic this hormone at pharmacological doses, creating powerful appetite suppression.

Mazdutide does all of this and adds a second channel. It also activates the glucagon receptor. Glucagon is often thought of as insulin’s opposite: it raises blood sugar by prompting the liver to release stored glucose. But glucagon has another critical role that has long interested obesity researchers: it increases energy expenditure. When glucagon receptors are activated in the liver and brown adipose tissue, the body can burn more calories at rest^[4]. It can also promote lipid oxidation—the breakdown of fats for fuel—and reduce fat accumulation in the liver^[5].

The theoretical elegance of a dual GLP-1/glucagon agonist lies in tackling obesity from both sides of the energy equation simultaneously. The GLP-1 component reduces energy intake by curbing hunger. The glucagon component increases energy expenditure by boosting metabolic rate. This two-pronged strategy may explain why mazdutide’s weight-loss figures are so competitive despite the relatively short treatment duration. This feature also distinguishes mazdutide from tirzepatide, a dual GLP-1 and GIP receptor agonist—a different pairing with a different metabolic rationale^[6].

Mazdutide is not walking this innovative metabolic path alone. The dual-action GLP-1/glucagon agonist class had already gained strong clinical ground with survodutide, whose Phase 3 SYNCHRONIZE-1 trial was recently published, showing up to 13.0% weight loss in 76 weeks. Our analysis of this study was published on Vitalsdaily. While survodutide has stood out in late-stage trials for its significant benefits on liver fat and metabolic parameters, mazdutide’s Phase 2 data exhibits a faster and steeper weight loss curve, reaching 18.1% in the much shorter period of 32 weeks. The shared success of both agents proves that combining glucagon-mediated energy expenditure with GLP-1-induced appetite suppression is not an isolated experiment; it heralds the birth of a potent and independent new class of drugs poised to rewrite the rules in obesity and liver metabolism.

Notable Limitations

This is a phase 2 trial with 179 participants—sufficient to signal efficacy and identify safety concerns, but too small to draw definitive conclusions. The 20% discontinuation rate at the highest dose is not insignificant; for a medication that patients may need to take indefinitely, tolerability is at least as important as potency. Furthermore, we still lack long-term data on weight maintenance after drug cessation, cardiovascular outcomes, and effects on metabolic parameters like liver fat and lipid profiles over the long term. Larger phase 3 trials with more diverse populations will be essential to determine whether mazdutide’s promising early results translate into a durable clinical reality.

What This Means for Future Patients

Mazdutide is not yet a prescribable drug. But its phase 2 results send a clear signal: the field of obesity pharmacotherapy is rapidly expanding, and the drugs being developed today are fundamentally more effective than anything that existed just five years ago. For the approximately 42% of American adults living with obesity, this is profoundly meaningful news^[7]. More effective drugs with different mechanisms of action mean more options—and more options mean a greater chance of finding the right treatment for each individual patient.

The dual GLP-1/glucagon approach carries implications beyond weight loss alone. Glucagon receptor activation may improve fatty liver disease, a condition that affects a surprisingly large proportion of individuals with obesity and for which treatment options remain limited. If phase 3 data confirms both its weight-loss efficacy and favorable metabolic effects, mazdutide could carve out a unique niche in this increasingly crowded field—not as a substitute for existing treatments, but as a distinct tool built on a different biological foundation.

Scientific Sources

1. Hsia SH, et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet Diabetes Endocrinol. 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42628555/
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2032183
3. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018. DOI: 10.1016/j.cmet.2018.03.001
4. Habegger KM, et al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010. DOI: 10.1038/nrendo.2010.187
5. Day JW, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009. DOI: 10.1038/nchembio.209
6. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. DOI: 10.1056/NEJMoa2206038
7. Hales CM, et al. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. NCHS Data Brief. 2020. PMID: 32487284